Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 84-88, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-272500
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma.</p><p><b>METHODS</b>Eighty patients with relapsed and refractory non-Hodgkin's B cell lymphoma were chosen in our hospital from January 2009 to June 2012, and randomly were divided into 2 groups including the CHOPE regimen group (40 patients) and CHOPE plus thalidomide group (40 patients); and the clinical efficacy, the levels of sVEGF and LDH before and after treatment, the survival rate and the III-IV degree toxic side-effects in these 2 groups were compared.</p><p><b>RESULTS</b>The clinical efficacy of CHOPE+thalidomide group was significant higher than that of CHOPE group alone (P < 0.05). The levels of sVEGF and LDH after treatment in the CHOPE+thalidomide group was significantly higher than that in CHOPE group alone before treatment (P < 0.05). The survival rate in CHOPE+thalidomide group was significant higher than that in CHOPE group alone (P < 0.05). The median survival time in CHOPE+thalidomide group was significant longer than that in CHOPE group alone (P < 0.05). The incidence of III-IV degree toxic side effects was not significantly different between 2 these groups (P > 0.05).</p><p><b>CONCLUSION</b>Compared with CHOPE regimen alone, CHOPE regimen combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma can efficiently delay the disease progression, reduce tumor burden level, enhance the long-term survival rate, morever did not increase the risk of toxic side effects.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thalidomide
/
Vincristine
/
Blood
/
Prednisone
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Survival Rate
/
Lymphoma, B-Cell
/
Treatment Outcome
/
Cyclophosphamide
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS